Revolutionary Veterinary AI Platform Ditches Dense Documentation in Favor of Clear, Engaging Video Walkthrough MINNEAPOLIS, MN, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo.ai, the AI powered platform transforming how veterinary practices connect with pet parents, today announced something different: instead of another lengthy press release filled with jargon, they made a video. "Let's be honest," said John Lai, CEO at PetVivo Holdings (OTCQX: PETV; OTCID: PETVW). "Most tech launches are too complicated and to ...

Core Insights - PetVivo.ai has launched an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [2][4][9] Group 1: Company Overview - PetVivo Holdings, Inc. is focused on commercializing innovative medical products and therapeutics for companion animals and horses [2][12] - The company has introduced PetVivo.ai, an AI-driven Software-as-a-Service (SaaS) platform that enhances its existing product portfolio [3][10] Group 2: Market Opportunity - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet parents making up 57% of pet owners, who expect modern digital experiences [4][8] - There are approximately 30,000 veterinary practices in the U.S. and over 100,000 worldwide, indicating a large and under-digitized market for PetVivo.ai [8] Group 3: Product and Technology - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with pet owners, improving lead generation and customer engagement [5][10] - The platform has demonstrated a customer acquisition cost of $42.53, significantly lower than the typical $80–$400 spent by veterinary practices [2][7] Group 4: Financial Metrics - In a beta program, the median practice acquired 47 new clients over six months, achieving a blended customer acquisition cost of $42.53 [5][7] - The platform offers a pricing model starting at $1,999 per month, with gross margins between 80% and 90% [7] Group 5: Competitive Advantages - PetVivo.ai holds a first-mover advantage in the AI-driven veterinary market, with no direct competitors and strong network effects [10] - The company has established relationships with 1,200 veterinary clinic distributors and plans to expand to over 7,000 [10] Group 6: Valuation Potential - The launch of PetVivo.ai is expected to transition the company from traditional medical device revenue multiples (1–2x) to AI SaaS multiples (15–30x), indicating potential valuation upside [9]

Core Insights - PetVivo Holdings, Inc. has launched PetVivo.ai, an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [1][3][4] - The company is shifting from traditional medical device sales to a high-margin AI Software-as-a-Service (SaaS) model, which offers recurring revenue and scalability [2][5] Industry Context - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet owners making up 57% of all pet owners, who expect modern digital experiences [3] - Veterinary practices currently rely on outdated marketing methods, leading to high customer acquisition costs ranging from $80 to $400 per new client [3][4] Company Strategy - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with engaged pet parents, generating qualified leads at a cost of $3 per pet parent, compared to traditional methods costing $15 to $45 [4][6] - The platform's beta program showed that the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53, achieving significant savings [4][6] Financial Metrics - The platform is expected to achieve gross margins of 80-90% and a lifetime value to customer acquisition cost (LTV/CAC) ratio of 25:1 [6] - Projections indicate that by Year 1, the company could reach $12 million in annual recurring revenue (ARR) with 500 practices, scaling to $360 million ARR with 10,000 practices by Year 5 [6] Market Opportunity - PetVivo.ai targets approximately 30,000 U.S. veterinary practices and over 100,000 globally, with strong scaling potential even under conservative adoption forecasts [5][6] - The launch is seen as a catalyst for re-evaluating the company's valuation, transitioning from traditional medical device revenue multiples of 1-2x to AI SaaS multiples of 15-30x [5][7] Competitive Advantages - PetVivo.ai holds a first-mover advantage with no direct AI competitors and strong two-sided network effects, supported by existing relationships with 1,200 veterinary clinic distributors [7] - Deep integrations with practice management systems are expected to facilitate adoption and reduce onboarding friction [7] Commercial Launch - Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups, offering a 14-day free trial and three pricing tiers [8]

Core Insights - PetVivo Holdings, Inc. is set to launch its veterinary platform in Q1 2026, supported by a comprehensive technical whitepaper from its AI technology partner, Digital Landia Holding Corp. [1][11] Technical Validation - The whitepaper confirms the technical foundation of PetVivo's exclusive 10-year licensing agreement, showcasing a multi-agent AI architecture that offers significant clinical and economic benefits for veterinary practices [2][9]. - The CEO of PetVivo emphasized that the whitepaper validates a production-ready AI framework with clinical utility and enterprise-grade architecture [3]. Framework Capabilities - The AI framework addresses key challenges in veterinary practices, including a 90% to 98% reduction in client acquisition costs and universal diagnostic assistance through nine specialized AI agents [4]. - The platform is designed to enhance access to the Gen Z market with a mobile-first consumer experience [4]. Intellectual Property - The whitepaper outlines five patent-pending innovations that protect the core functionality of the AgenticPet framework, providing competitive advantages under the licensing agreement [5]. Enterprise Architecture - The architecture is tailored for veterinary practices, featuring end-to-end encryption, blockchain audit trails, and HIPAA-aligned privacy frameworks, ensuring over 99.9% uptime reliability [6][7]. Distribution Network - PetVivo has an established distribution network, including a partnership with Veterinary Growth Partners, which has over 7,300 veterinary professional members, positioning the company for rapid deployment of the AgenticPet platform [7]. Strategic Rationale - The exclusive 10-year licensing agreement reflects PetVivo's confidence in the framework's competitive positioning and potential revenue streams, including B2B subscriptions and lead-generation fees [9]. Partnership Milestones - The publication of the whitepaper marks the third major milestone in the PetVivo–Digital Landia partnership, following the strategic alliance announcement and the exclusive licensing agreement [10]. Upcoming Launch - The technical foundation supports a dual-platform launch in Q1 2026, featuring both a B2C app and a B2B veterinary platform with AI diagnostic assistance [11].

Core Insights - PetVivo Holdings, Inc. reported a 51% increase in revenues for the second quarter of fiscal year 2026, totaling $303,000, driven by the introduction of the new product line PrecisePRP and expansion into the companion animal market [7][19][21] - The company has successfully entered the European market through a partnership with Nupsala Group, enhancing its distribution capabilities [6][16] - PetVivo's strategic collaborations, including with Digital Landia and Commonwealth Markets, are expected to enhance product adoption and market presence [10][17][18] Fiscal Q2 Financial Highlights - Revenues increased to $303,000, up 51% from the same quarter last year, marking a record for the second fiscal quarter [7][19] - Gross profit rose to $220,000, with a gross margin of 72.6%, an improvement from 63.8% in the previous quarter [20] - Operating loss increased to $2.1 million, while net loss rose to $3.0 million, reflecting increased sales and marketing expenses [21][22] Fiscal Q2 Operational Highlights - The company engaged additional distributors to support domestic and international expansion, with national distributor network sales increasing by 35% [7][19] - PetVivo's flagship product, Spryng with OsteoCushion Technology, has been adopted by over 1,200 veterinary clinics across the U.S. [17] - The company launched three new continuing education courses for veterinary professionals to enhance expertise in osteoarthritis and regenerative modalities [13] Strategic Partnerships and Innovations - A strategic partnership with Digital Landia aims to integrate AI technology into PetVivo's veterinary products, potentially reducing client acquisition costs significantly [10][18] - The collaboration with Commonwealth Markets has led to the integration of Spryng and PrecisePRP into care protocols for thoroughbred horses [17] - Ongoing research with PiezoBioMembrane is focused on developing biodegradable piezoelectric materials for regenerative applications [12][15] Financial Outlook - Management anticipates continued record growth for the full fiscal year ending March 31, 2026, driven by the expansion of Spryng and PrecisePRP [24][25] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [18]

Core Insights - PetVivo Holdings, Inc. will hold a conference call on November 14, 2025, to discuss its fiscal second quarter results for the period ending September 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary PetVivo Animal Health, Inc., specializing in biomedical devices for companion animals [4] - The company aims to bring veterinary medical devices to market faster than more regulated pharmaceuticals, enhancing revenue timelines [4] - PetVivo holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5] Upcoming Events - The conference call will include a presentation by management followed by a Q&A session [2] - Dial-in information for the conference call includes a toll-free number and a specific conference ID and passcode [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has appointed Josh Ruben to its Board of Directors, enhancing its leadership team with expertise in healthcare finance and corporate strategy [1][2][4] - Ruben's background includes significant experience in executing multi-billion-dollar mergers and acquisitions, which will support PetVivo's growth and market expansion efforts [2][4] - The company focuses on innovative medical therapeutics for companion animals, particularly in treating osteoarthritis and joint conditions [2][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, specifically targeting the commercialization of medical devices and therapeutics for companion animals [6] - The company aims to leverage human therapies for animal treatment, allowing for a quicker market entry compared to traditional pharmaceuticals [6] - PetVivo has a diverse product pipeline, including its lead product SPRYNG, which utilizes OsteoCushion technology for joint-related afflictions in animals [7] Leadership and Strategy - Josh Ruben, as the Managing Director of Life Sciences at Trinity Capital, brings a wealth of experience in venture lending and investment banking, particularly in life sciences [4][5] - His expertise will be instrumental in guiding PetVivo's capital strategy and maximizing value creation across veterinary and emerging human applications [5] - The company holds a portfolio of twelve patents and six trade secrets, protecting its innovative biomaterials and production processes [7]

Core Insights - PetVivo Holdings, Inc. has entered into a 10-year exclusive white-label licensing agreement with Digital Landia Holding Corp for the Agentic Pet AI technology, aimed at addressing high client acquisition costs and engaging the growing Gen Z pet parent demographic [1][13]. Industry Overview - The veterinary industry is experiencing a demographic shift, with Gen Z pet parenthood increasing by 43.5% in 2024, making Gen Z and Millennials account for 57% of all pet parents in the U.S. [3][5]. - Traditional marketing strategies in veterinary practices are failing to connect with the tech-savvy Gen Z demographic, which presents a significant opportunity for innovative solutions [5]. Technology and Solutions - The Agentic Pet AI technology can reduce client acquisition costs by 90% to 98%, lowering costs from $50-$150+ per client to just $1.50-$5.00 per targeted outreach [2][9]. - The technology includes a freemium app with nine specialized AI diagnostic agents that track pet health, allowing pet parents to share health data seamlessly with veterinary practices [7][8]. Economic Impact - The partnership is expected to transform client acquisition for veterinary practices, with a case study showing a reduction in acquisition costs from $80-$120 to $3.50 per client, alongside significant time savings in patient history gathering [11][12]. - The overall efficiency of consultations is projected to improve by 20%, with a 30% increase in preventive care visits due to early issue identification through AI [12]. Market Opportunity - PetVivo is entering a $4.9 billion U.S. veterinary AI market with over 30,000 addressable clinics, leveraging existing relationships with more than 1,000 veterinary clinics for immediate distribution [14]. - The company reported a 141% year-over-year growth in Q1 FY2026, with fiscal 2025 revenue reaching $1.13 million, indicating strong market momentum [14]. Strategic Positioning - The exclusive agreement provides PetVivo with a competitive advantage for 10 years, creating multiple revenue streams through B2B subscriptions and lead generation fees [15]. - The dual-platform launch in Q1 2026 is expected to create immediate network effects, enhancing the value proposition for both pet parents and veterinary practices [13].

Core Insights - PetVivo Animal Health, Inc. has entered into a Vendor Partner Agreement with Veterinary Growth Partners to promote its innovative veterinary products [1][5] - The agreement aims to enhance the accessibility and adoption of PetVivo's flagship products, Spryng with OsteoCushion Technology and PrecisePRP, among veterinary practices [2][5] Company Overview - PetVivo Holdings, Inc. is focused on the commercialization of biomedical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment solutions [6][7] - The company has a robust pipeline of products protected by twelve patents and six trade secrets, including Spryng and PrecisePRP [7] Product Details - Spryng with OsteoCushion Technology is an intra-articular injectable device designed to manage joint pain and improve joint mechanics in animals [3] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product that provides a consistent dose of 4 billion platelets per vial, designed for easy use by veterinarians [4] Partnership Impact - The collaboration with Veterinary Growth Partners is expected to expand national availability and enhance purchasing efficiency for veterinary practices seeking non-pharmaceutical solutions [5][8] - Veterinary Growth Partners supports over 7,300 veterinary members across the U.S., providing a significant network for PetVivo's products [1][2]

Core Insights - PetVivo Holdings, Inc. has entered into note conversion agreements with four existing shareholders to convert $2,018,155 of outstanding promissory notes into 3,669,806 shares of common stock, effectively eliminating over $2 million of debt from its balance sheet [1][4] Group 1: Financial Developments - The total outstanding debt consisted of a principal amount of $1,850,000 and accrued interest of $168,155 [1] - The conversion prices of the notes ranged from $0.50 to $0.75 per share [1] - The successful completion of the note conversion strengthens the company's financial position and allows for more resources to be directed towards product commercialization [4] Group 2: Product Information - PetVivo's signature products include SPRYNG with OsteoCushion Technology, an injectable veterinary medical device that aids in managing joint pain and restoring joint mechanics [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for intra-articular administration in dogs and horses, providing a consistent dose of 4 billion platelets per vial [3][7] Group 3: Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has a robust pipeline of products protected by twelve patents and six trade secrets [7]